PSI TFA

Cat. No.: HY-P1258A

Molecular Formula: $C_{34}H_{51}F_3N_4O_{10}$

Molecular Weight: 732.78

Target: Proteasome

Pathway: Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

PSI (TFA) is a potent proteasome inhibitor. PSI (TFA) inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI (TFA) can be used for the research of Kaposi's sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas[1].

IC_{50} & Target

CC50: 205 nM (BJAB cells); 190 nM (Ramos cells); 22.0 nM (BC3 cells); 53.0 nM (BCBL1 cells)[1]

In Vitro

PSI (TFA) (24 h) inhibits the proliferation with CC_{50} values of 205, 190, 22.0, 53.0 nM for BJAB, Ramos, BC3, BCBL1 cells, respectively)[1].

PSI (TFA) (50 nM; 6 h) increases caspase-3/7 activity by 8-fold compared with control[1].

PSI (TFA) (50 nM; 6 h) decreases the transcriptional activity of NF-κB by 52%[1].

PSI (TFA) (1, 5 nM; 3 days) inhibits the growth of BC3 cells at a high concentration (5 nM)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line:	BC3, BCBL1, Ramos, BJAB cells
Concentration:	
Incubation Time:	24 h
Result:	Inhibited the proliferation of primary effusion lymphoma (PEL) cells at low nanomolar concentrations (CC_{50} values of 205, 190, 22.0, 53.0 nM for BJAB, Ramos, BC3, BCBL1 cells, respectively).

Western Blot Analysis[1]

Cell Line:	HBL6 cells
Concentration:	50 nM
Incubation Time:	6 h
Result:	Decreased the NF-κB activity by 52%.

REFERENCES

[1]. Saji C, et al. Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells. Biochem Biophys Res Commun. 2011; 415(4):573-8.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA